Axa’s Kite Pharma, Inc. KITE Stock Holding History

Axa’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-74,667	Closed	-$4.6M	–	1484
2015 Q4	$4.6M	Sell	74,667 -10,569	-12%	-$744K	0.02%	582
2015 Q3	$4.75M	Buy	85,236 +58,337	+217%	+$3.67M	0.02%	586
2015 Q2	$1.64M	Hold	26,899	–	–	0.01%	835
2015 Q1	$1.55M	Buy	26,899 +1,899	+8%	+$127K	0.01%	859
2014 Q4	$1.44M	Buy	+25,000	New	+$1.05M	0.01%	878

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Axa's KITE Position: Q1 2016 in Review

Axa sold out of Kite Pharma, Inc. (KITE) in Q1 2016, closing a stake of 74,667 shares — an estimated $4.6M sold.

Axa first reported a position in KITE in Q4 2014 and held it in 5 quarters. The position peaked at $4.75M in Q3 2015. 171 funds tracked by Wall St. Rank hold KITE as of Q1 2016.

Axa reported no remaining Kite Pharma, Inc. position as of Q1 2016 after selling out during the quarter.
Axa sold 74,667 Kite Pharma, Inc. shares in Q1 2016, an estimated $4.6M.
Axa first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 5 quarters.
Axa's Kite Pharma, Inc. position peaked at $4.75M in Q3 2015.
171 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2016.

Based on Axa's 13F filing for Q1 2016, filed 13 May 2016.